| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_129e393582e6bdf4029baf2206522f45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e2dd5830cccde9f8e2b9c5828d7ebf9e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-204
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-008 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 |
| filingDate |
1991-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4ad3f21f8e30adfb84075a1da49b4aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_453756e7721e9c1164adf9363d2bbe84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3830c96affca192b411141b8329defb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73ea4f706f419747b3fc4884d6ee4f89 |
| publicationDate |
1992-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0477386-A1 |
| titleOfInvention |
FORMULATION OF AN AEROSOL FOR PHARMACEUTICAL USE COMPRISING SOLID POLYPEPTIDE MICROPARTICLES AND PREPARATION METHOD. |
| abstract |
The invention relates to an aerosol formulation for pharmaceutical use of a biologically active polypeptide which is an interferon of human origin or an interleukin of human origin and which is characterized in that said polypeptide is in the form of micronized solid particles having a predetermined average diameter. An aqueous solution of the polypeptide and lyophilized and then ground until a suitable particle size is obtained whose average diameter is between 0.5 and 10, in order to target an upper or lower respiratory tract. The polypeptide suspension used for the aerosol is prepared in a graduated dose pressure inhaler administered by oral inhalation, and has been found to produce the local and systemic effects sought after testing in animals. The biological response obtained with the aerosol to the polypeptide can very well be compared to the response obtained following parenteral administration. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8333958-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7892531-B2 |
| priorityDate |
1990-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |